融合多孔硅纳米粒子递送 VEGF-siRNA 有效治疗视网膜新生血管渗漏。
Effective treatment of retinal neovascular leakage with fusogenic porous silicon nanoparticles delivering VEGF-siRNA.
机构信息
Department of Chemistry & Biochemistry, University of California, San Diego, CA 92093, USA.
Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA.
出版信息
Nanomedicine (Lond). 2022 Nov;17(27):2089-2108. doi: 10.2217/nnm-2022-0255. Epub 2023 Feb 7.
To evaluate an intravitreally injected nanoparticle platform designed to deliver VEGF-A siRNA to inhibit retinal neovascular leakage as a new treatment for proliferative diabetic retinopathy and diabetic macular edema. Fusogenic lipid-coated porous silicon nanoparticles loaded with VEGF-A siRNA, and pendant neovascular integrin-homing iRGD, were evaluated for efficacy by intravitreal injection in a rabbit model of retinal neovascularization. For 12 weeks post-treatment, a reduction in vascular leakage was observed for treated diseased eyes versus control eyes (p = 0.0137), with a corresponding reduction in vitreous VEGF-A. Fusogenic lipid-coated porous silicon nanoparticles siRNA delivery provides persistent knockdown of VEGF-A and reduced leakage in a rabbit model of retinal neovascularization as a potential new intraocular therapeutic.
评估一种旨在将 VEGF-A siRNA 递送至抑制视网膜新生血管渗漏的玻璃体注射纳米颗粒平台，作为治疗增生性糖尿病视网膜病变和糖尿病性黄斑水肿的新方法。 负载 VEGF-A siRNA 和悬挂新生血管整合素靶向 iRGD 的融合脂质包覆多孔硅纳米颗粒，通过兔视网膜新生血管模型的玻璃体注射评估其疗效。 在治疗后 12 周，与对照眼相比，治疗患病眼的血管渗漏减少（p=0.0137），玻璃体内 VEGF-A 相应减少。 融合脂质包覆多孔硅纳米颗粒 siRNA 递送可在兔视网膜新生血管模型中持续敲低 VEGF-A 并减少渗漏，有望成为新的眼内治疗方法。
Zotero 插件